Skip to main
DVAX
DVAX logo

Dynavax Technologies (DVAX) Stock Forecast & Price Target

Dynavax Technologies (DVAX) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 44%
Hold 11%
Sell 0%
Strong Sell 11%

Bulls say

Dynavax Technologies Corp. has demonstrated strong growth in its HEPLISAV-B sales, achieving $71.1 million in 4Q24, which reflects a 39% year-over-year increase, and an overall annual sales figure of $268.4 million for FY24, a 26% increase. The company is well-positioned to capitalize on the expanding hepatitis B vaccination market, projected to exceed $900 million by 2030, with expectations for HEPLISAV-B to secure at least a 60% market share and continue to experience double-digit annual growth rates. Additionally, Dynavax's intention to implement a $400 million share repurchase program underscores its confidence in the company's financial health and future performance.

Bears say

Dynavax Technologies faces significant risks that contribute to a negative outlook for its stock, including the potential failure of its clinical candidates to meet efficacy and safety standards, which could hinder regulatory approval and commercialization. Additionally, the company may struggle to effectively market its products due to competitive pressures, potential litigation risks, and challenges in securing acceptable partnership agreements for its pipeline candidates. Financially, Dynavax has shown a pattern of losses and has not established a consistent profitability track record, as evidenced by its fourth-quarter 2024 revenue and earnings per share figures, which, although slightly above estimates, indicate ongoing financial vulnerabilities.

Dynavax Technologies (DVAX) has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 44% recommend Buy, 11% suggest Holding, 0% advise Selling, and 11% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dynavax Technologies and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dynavax Technologies (DVAX) Forecast

Analysts have given Dynavax Technologies (DVAX) a Buy based on their latest research and market trends.

According to 9 analysts, Dynavax Technologies (DVAX) has a Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.89, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.89, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dynavax Technologies (DVAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.